Company Description
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases.
The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention.
In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions.
vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S.
The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 30, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Paul J. Sekhri M.Sc. |
Contact Details
Address: 3980 Premier Dr, Suite 310 High Point, North Carolina 27265 United States | |
| Phone | 336-841-0300 |
| Website | vtvtherapeutics.com |
Stock Details
| Ticker Symbol | VTVT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001641489 |
| CUSIP Number | 918385105 |
| ISIN Number | US9183852048 |
| Employer ID | 47-3916571 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul J. Sekhri M.Sc. | Chief Executive Officer, President and Director |
| Steven Tuch M.B.A. | Executive Vice President and Chief Financial Officer |
| Barry Brown | Chief Accounting Officer |
| Richard S. Nelson | Executive Vice President of Corporate Development and Director |
| Dr. Carmen Valcarce Ph.D. | Chief Scientific Officer and Executive Vice President |
| Vanessa McDade | Chief Administrative Officer |
| Elizabeth M. Keiley | Executive Vice President and General Counsel |
| Dr. Thomas Strack M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 22, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 10-K | Annual Report |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 7, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 5, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Mar 5, 2024 | SC 13D | General statement of acquisition of beneficial ownership |